|
Name |
(+)-Aspermytin A
|
Molecular Formula | C16H26O3 | |
IUPAC Name* |
1-[(1R,2R,4aR,6S,8aS)-2-hydroxy-1,2,6-trimethyl-4a,5,6,7,8,8a-hexahydronaphthalen-1-yl]-3-hydroxypropan-1-one
|
|
SMILES |
C[C@H]1CC[C@H]2[C@H](C1)C=C[C@@]([C@]2(C)C(=O)CCO)(C)O
|
|
InChI |
InChI=1S/C16H26O3/c1-11-4-5-13-12(10-11)6-8-15(2,19)16(13,3)14(18)7-9-17/h6,8,11-13,17,19H,4-5,7,9-10H2,1-3H3/t11-,12-,13-,15+,16-/m0/s1
|
|
InChIKey |
RYBXJAJHOPCXHS-RDUHTLEXSA-N
|
|
Synonyms |
(+)-Aspermytin A; CHEMBL4162012; CHEBI:181609; NCGC00380110-01; 1-[(1R,2R,4aR,6S,8aS)-2-hydroxy-1,2,6-trimethyl-4a,5,6,7,8,8a-hexahydronaphthalen-1-yl]-3-hydroxypropan-1-one; NCGC00380110-01_C16H26O3_1-Propanone, 3-hydroxy-1-[(1R,2R,4aR,6S,8aS)-1,2,4a,5,6,7,8,8a-octahydro-2-hydroxy-1,2,6-trimethyl-1-naphthalenyl]-
|
|
CAS | NA | |
PubChem CID | 9993091 | |
ChEMBL ID | CHEMBL4162012 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 266.38 | ALogp: | 2.5 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 57.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.772 |
Caco-2 Permeability: | -4.466 | MDCK Permeability: | 0.00002060 |
Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.061 |
Human Intestinal Absorption (HIA): | 0.066 | 20% Bioavailability (F20%): | 0.07 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.99 | Plasma Protein Binding (PPB): | 21.84% |
Volume Distribution (VD): | 0.707 | Fu: | 49.35% |
CYP1A2-inhibitor: | 0.049 | CYP1A2-substrate: | 0.743 |
CYP2C19-inhibitor: | 0.216 | CYP2C19-substrate: | 0.864 |
CYP2C9-inhibitor: | 0.06 | CYP2C9-substrate: | 0.607 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.106 |
CYP3A4-inhibitor: | 0.574 | CYP3A4-substrate: | 0.421 |
Clearance (CL): | 6.967 | Half-life (T1/2): | 0.883 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.211 |
Drug-inuced Liver Injury (DILI): | 0.119 | AMES Toxicity: | 0.088 |
Rat Oral Acute Toxicity: | 0.08 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.808 | Carcinogencity: | 0.371 |
Eye Corrosion: | 0.552 | Eye Irritation: | 0.956 |
Respiratory Toxicity: | 0.306 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003603 | 0.750 | D08PIQ | 0.305 | ||||
ENC003690 | 0.651 | D0I5DS | 0.305 | ||||
ENC005218 | 0.651 | D07DVK | 0.299 | ||||
ENC003775 | 0.500 | D0CW1P | 0.299 | ||||
ENC003792 | 0.493 | D0IT2G | 0.299 | ||||
ENC003781 | 0.437 | D03HYX | 0.286 | ||||
ENC003798 | 0.368 | D0F1EX | 0.286 | ||||
ENC003119 | 0.363 | D03IKT | 0.286 | ||||
ENC004028 | 0.348 | D0FL5V | 0.286 | ||||
ENC003491 | 0.341 | D0D1SG | 0.284 |